CLAIM CARD
The current evidence for healthspan and quality of life outcomes is defined by this single planned trial within the corpus. No other studies in the included sources provide direct human data on rapamycin or its analogues for similar healthspan endpoints. This creates a situation where the mechanistic plausibility for benefit is not yet accompanied by completed human RCT data within this curated set. The tension lies between strong preclinical rationale and the absence of concluded human efficacy evidence for this specific outcome class.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025